[89Zr]Zr-DFO-SHR1920

[89Zr]Zr-DFO-SHR1920 is a diagnostic radiopharmaceutical designed for immunoPET imaging. It comprises the humanized anti-TROP2 monoclonal antibody, SHR1920, which is radiolabeled with the positron-emitting radionuclide Zirconium-89 (89Zr) through the chelator desferrioxamine (DFO). This agent is utilized to non-invasively visualize and quantify the distribution of TROP2-expressing cells in cancer patients. Specifically, it serves as a companion diagnostic to evaluate tracer uptake in primary and metastatic tumor lesions, particularly in pancreatic cancer, before initiating treatment with TROP2-directed therapies like SHR-A1921 (an antibody-drug conjugate that uses SHR1920 as its antibody component).